Physician profile
Patrick Gramith
NPI 1023497211
$616.32
in general payments reported to CMS, 2019-2025
17 companies · $15.62 in 2025
The $15.62 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $28.57 · 2021: $13.31 · 2023: $165 · 2024: $113 · 2025: $15.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $84.41 | 2021-2024 | |
| Novo Nordisk INC | $79.11 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $77.50 | 2019-2020 | |
| Glaxosmithkline, LLC. | $69.62 | 2019-2024 | Arexvy |
| Pfizer INC. | $45.88 | 2019-2024 | |
| Amgen INC. | $35.79 | 2019 | |
| Lilly USA, LLC | $28.88 | 2023 | Jardiance |
| Medtronic, INC. | $26.90 | 2024 | Interstim |
| Eisai INC. | $23.68 | 2019 | |
| Allergan, INC. | $23.14 | 2019-2020 | |
| Exact Sciences Corporation | $22.88 | 2023 | Cologuard Collection Kit |
| Avanir Pharmaceuticals, INC. | $22.55 | 2019 | |
| Alkermes, INC. | $17.86 | 2019 | |
| Merck Sharp & Dohme LLC | $16.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.98 | 2023 | Trintellix |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $14.96 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gramith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.